Literature DB >> 9116499

High-level expression and purification of the major birch pollen allergen, Bet v 1.

K Hoffmann-Sommergruber1, M Susani, F Ferreira, P Jertschin, H Ahorn, R Steiner, D Kraft, O Scheiner, H Breiteneder.   

Abstract

Bet v 1, the single major allergen from birch pollen, shares IgE epitopes with all major tree pollen allergens from closely related species such as alder, hazel, hornbeam, beech, and European chestnut. Because of high sequence homologies among these allergens and the well-studied cross-reactivities on B cell epitopes, Bet v 1 is a representative model protein which can be used for in vitro studies. The cDNA coding for Bet v 1, the single major allergen from birch pollen, was cloned into the T7-based Escherichia coli expression system pMW 175/BL21(DE3) and synthesized as a nonfusion protein. In contrast to other E. coli systems (e.g., pKK233-2/JM105), this system produces high levels of readily extractable proteins corresponding to 5-10% of E. coli total protein, the percentage varying with culture conditions. The overall yield was 8-10 mg of purified recombinant protein per liter of culture medium. The recombinant allergen was purified by several steps, including ion-exchange and hydrophobic interaction chromatography. The purified recombinant allergen showed identical immunological properties with the respective natural counterpart. The use of recombinant allergens of high purity is expected to result in more accurate diagnostic procedures, but possibly also in a superior immunotherapy of Type I allergic diseases when compared with methods using crude allergen extracts containing various amounts of allergen concentrations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9116499     DOI: 10.1006/prep.1996.0671

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  20 in total

1.  Molecular characterization of the S-layer gene, sbpA, of Bacillus sphaericus CCM 2177 and production of a functional S-layer fusion protein with the ability to recrystallize in a defined orientation while presenting the fused allergen.

Authors:  Nicola Ilk; Christine Völlenkle; Eva M Egelseer; Andreas Breitwieser; Uwe B Sleytr; Margit Sára
Journal:  Appl Environ Microbiol       Date:  2002-07       Impact factor: 4.792

2.  Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer.

Authors:  Raffaela Campana; Susanne Vrtala; Bernhard Maderegger; Yuliya Dall'Antonia; Domen Zafred; Katharina Blatt; Harald Herrmann; Margarete Focke-Tejkl; Ines Swoboda; Sandra Scheiblhofer; Anna Gieras; Angela Neubauer; Walter Keller; Peter Valent; Josef Thalhamer; Susanne Spitzauer; Rudolf Valenta
Journal:  Mol Immunol       Date:  2010-11-18       Impact factor: 4.407

3.  Antigen aggregation decides the fate of the allergic immune response.

Authors:  Nadja Zaborsky; Marietta Brunner; Michael Wallner; Martin Himly; Tanja Karl; Robert Schwarzenbacher; Fatima Ferreira; Gernot Achatz
Journal:  J Immunol       Date:  2009-12-07       Impact factor: 5.422

4.  Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms.

Authors:  Benjamin Punz; Litty Johnson; Mark Geppert; Hieu-Hoa Dang; Jutta Horejs-Hoeck; Albert Duschl; Martin Himly
Journal:  Pharmaceutics       Date:  2022-05-21       Impact factor: 6.525

5.  Molecular characterization of recombinant T1, a non-allergenic periwinkle (Catharanthus roseus) protein, with sequence similarity to the Bet v 1 plant allergen family.

Authors:  Sylvia Laffer; Said Hamdi; Christian Lupinek; Wolfgang R Sperr; Peter Valent; Petra Verdino; Walter Keller; Monika Grote; Karin Hoffmann-Sommergruber; Otto Scheiner; Dietrich Kraft; Marc Rideau; Rudolf Valenta
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

6.  Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.

Authors:  Susanne Vrtala; Monika Fohr; Raffaela Campana; Christian Baumgartner; Peter Valent; Rudolf Valenta
Journal:  Vaccine       Date:  2011-01-05       Impact factor: 3.641

7.  Crystallographically mapped ligand binding differs in high and low IgE binding isoforms of birch pollen allergen bet v 1.

Authors:  Stefan Kofler; Claudia Asam; Ulrich Eckhard; Michael Wallner; Fátima Ferreira; Hans Brandstetter
Journal:  J Mol Biol       Date:  2012-05-23       Impact factor: 5.469

8.  The influence of recombinant production on the immunologic behavior of birch pollen isoallergens.

Authors:  Michael Wallner; Martin Himly; Angela Neubauer; Anja Erler; Michael Hauser; Claudia Asam; Sonja Mutschlechner; Christof Ebner; Peter Briza; Fatima Ferreira
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

9.  Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE.

Authors:  Kavita Reginald; Julia Eckl-Dorna; Domen Zafred; Margarete Focke-Tejkl; Christian Lupinek; Verena Niederberger; Walter Keller; Rudolf Valenta
Journal:  Immunol Cell Biol       Date:  2012-12-11       Impact factor: 5.126

10.  Engraftment of retrovirally transduced Bet v 1-GFP expressing bone marrow cells leads to allergen-specific tolerance.

Authors:  Martina Gattringer; Ulrike Baranyi; Nina Pilat; Karin Hock; Christoph Klaus; Elisabeth Buchberger; Haley Ramsey; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  Immunobiology       Date:  2013-03-30       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.